Why Isn't Regenerative Medicine Covered by Insurance? A Physician's Honest Answer

PRP and other regenerative treatments aren't covered by insurance, and patients deserve a straight answer about why. Dr. Matt Kiok explains what insurance actually pays for, what "experimental" really means, and what cash-pay care buys instead.

Why won't insurance cover PRP and other regenerative medicine treatments?

Most patients hear it in the same visit where they first hear about PRP or prolotherapy: insurance won't cover this. The reaction usually comes in two parts: frustration first, because everything else along the way was covered, and then suspicion, because if this really worked, wouldn't insurance pay for it?

The short answer: insurers classify PRP and most regenerative treatments as "experimental" or "investigational," and that label is a financial classification, not a clinical judgment about whether a treatment works. Understanding why the label exists starts with what insurance actually covers, and what it leaves out.

What does insurance actually cover for joint, tendon, and nerve pain?

Insurance covers a standard pathway, and it covers it well: the office visit, the X-ray or MRI, a course of physical therapy, anti-inflammatories, a cortisone injection or several, and eventually surgery. Every step on that pathway is familiar, billable under long-established codes, and backed by decades of precedent, because that’s what coverage is: a list of services a payer has agreed in advance to reimburse.

Notice what the pathway is built around: each covered step either manages symptoms or, at the extreme end, waits until the problem is at its breaking point before trying to rescue it with surgery. Treatments that work with the body's own healing response, aimed at injuries too damaged to resolve on their own but not damaged enough to justify surgery, are largely absent from the list. That gap is where a large share of chronic tendon and joint problems live.

Why is PRP called "experimental" or "investigational"?

Those words carry a lot of weight in denial letters, so it's worth being precise about what they're doing.

Insurance is a business, and a patient who gets better is a patient who spends less. Insurance companies also aren't just in the insurance business anymore: many own hospitals and pharmacy benefit managers, and they have financial relationships with the entire chain of how you get treated. A treatment with the potential to actually heal a damaged tendon or joint sits awkwardly in that model, because a patient who heals doesn't need the cortisone shot every three months, the follow-up medications, or the surgery and rehabilitation that come after it. Repeat customers are the model, and getting better disrupts it.

So when you call to ask why a treatment isn't covered, and you're told it's "not medically necessary" or "still experimental," it helps to understand what that language is doing. It isn't a clinical determination about your injury; it's a financial classification, set by committee across millions of members and revisited slowly, if at all. It tells you where a treatment sits in a reimbursement system. It doesn't tell you whether the treatment is right for the injury in front of you.

Does "not covered" mean it doesn't work?

No. The science on PRP for certain orthopedic conditions is real and growing, and the reason it's not on your plan has nothing to do with whether it works.

That said, a responsible clinic is honest about where the science stands. The evidence for treatments like PRP is strongest in specific situations: partial tears rather than complete ones, and earlier arthritis rather than bone-on-bone. The list of conditions with strong support will look different a year from now. Whether a non-covered treatment makes sense is a per-patient, per-injury question, and that is exactly the kind of question a coverage committee cannot answer. Only a diagnosis can.

As a reminder, PRP is also not interchangeable between clinics. The outcome of a PRP injection depends on three critical factors: patient health status, physician “recipe,” and accurate delivery to the exact area of injury. To insurance companies, all PRP is treated equally, even though reality could not be further from their perception.

What does cash-pay care actually buy?

Mostly, it buys the two things a coverage-driven visit rarely has room for: time and diagnostics.

At OASIS, an initial consultation is a full hour with the physician, and it includes a comprehensive medical interview, a physical examination, and a diagnostic musculoskeletal ultrasound performed in the office the same day, with no referral and no authorization process. Ultrasound has resolution superior to MRI for soft tissue, with one advantage MRI can't match: the tissue can be imaged while it moves, so a partial tear that looks intact at rest can show up clearly under load.

It also buys an unconflicted answer. A cash-pay evaluation has no coverage desk shaping the recommendation, and sometimes the honest conclusion of that hour is that surgery is the right call, or that a covered treatment is the better fit for now. That is the evaluation working correctly, and it's the reason OASIS doesn't take insurance: treatment plans are created in person, physician and patient, and carried out on a timeline that fits your goals rather than an authorization queue.

Who is this path not for?

A fully torn tissue or an end-stage, bone-on-bone joint is surgery territory, and no injection changes that. If you only need a quick fix to get through the next couple of months, a covered cortisone shot may still have a place for you. Regenerative medicine serves the patients in the middle: an injury too damaged to heal on its own, but not damaged enough to need surgery. That’s where most of our knee pain and shoulder pain patients live. You can see how we draw that line, injury by injury, on our PRP services page.

What should you ask before paying out of pocket, anywhere?

These questions apply to any clinic, including this one.

1. Will I get a specific diagnosis before any treatment is recommended?

2. Do I need an MRI to be seen?

3. Is the injection guided by live ultrasound, or done blindly?

4. Would the person evaluating me tell me if surgery, or a covered option, were the better answer?

5. What does the plan include after the injection: follow-up, repeat imaging, rehabilitation?

6. What would make me a poor candidate?

A clinic that welcomes those questions is telling you something, and the more you understand how these decisions get made, the better equipped you are to make your own.

At OASIS, that starts with a diagnosis rather than a sales conversation. One hour with Dr. Kiok includes the full interview, the examination, and an in-office ultrasound. You'll leave knowing what's actually wrong and what will treat it, whether that's PRP, another regenerative option, surgery, or something else entirely.

No coverage desk. No authorization queue. No waiting to find out what's actually wrong.

Book a Consultation

Dr. Matt Kiok, MD, is the founder of OASIS Regenerative Medicine in Las Vegas, Nevada. He is a physician dedicated to advancing the emerging field of regenerative medicine, with a clinical focus on orthopedic soft tissue conditions, including tendon injuries, joint degeneration, and PRP-based orthobiologic treatments. Dr. Kiok uses diagnostic ultrasound as part of every initial consultation, allowing for real-time soft tissue evaluation without referral or separate imaging appointments.

This post is intended for educational purposes only and does not constitute medical advice. Individual outcomes vary. Consult a qualified physician to determine whether regenerative medicine is appropriate for your condition.